|
1
|
Zisman A, Pantuck AJ, Wieder J, et al:
Risk group assessment and clinical outcome algorithm to predict the
natural history of patients with surgically resected renal cell
carcinoma. J Clin Oncol. 20:4559–4566. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wada Y, Takahashi W, Kawano Y and Eto M:
Current status of pharmacotherapy against metastatic renal cell
carcinoma in Japan. Int J Urol. 19:284–295. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Müller A, Homey B, Soto H, et al:
Involvement of chemokine receptors in breast cancer metastasis.
Nature. 410:50–56. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guo RF and Ward PA: Role of C5a in
inflammatory responses. Annu Rev Immunol. 23:821–852. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cao Q, McIsaac SM and Stadnyk AW: Human
colonic epithelial cells detect and respond to C5a via apically
expressed C5aR through the ERK pathway. Am J Physiol Cell Physiol.
302:C1731–C1740. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kwan WH, van der Touw W, Paz-Artal E, Li
MO and Heeger PS: Signaling through C5a receptor and C3a receptor
diminishes function of murine natural regulatory T cells. J Exp
Med. 210:257–268. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chiou WF, Tsai HR, Yang LM and Tsai WJ:
C5a differentially stimulates the ERK1/2 and p38 MAPK
phosphorylation through independent signaling pathways to induced
chemotactic migration in RAW264.7 macrophages. Int Immunopharmacol.
4:1329–1341. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tsai HR, Yang LM, Tsai WJ and Chiou WF:
Andrographolide acts through inhibition of ERK1/2 and Akt
phosphorylation to suppress chemotactic migration. Eur J Pharmacol.
498:45–52. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nitta H, Wada Y, Kawano Y, et al:
Enhancement of human cancer cell motility and invasiveness by
anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88).
Clin Cancer Res. 19:2004–2013. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kawano Y, Diez S, Uysal-Onganer P,
Darrington RS, Waxman J and Kypta RM: Secreted frizzled-related
protein-1 is a negative regulator of androgen receptor activity in
prostate cancer. Br J Cancer. 100:1165–1174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shvarts O, Janzen N, Lam JS, et al:
RENCA/carbonic anhydrase-IX: a murine model of a carbonic
anhydrase- IX-expressing renal cell carcinoma. Urology.
68:1132–1138. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Berezovskaya O, Schimmer AD, Glinskii AB,
et al: Increased expression of apoptosis inhibitor protein XIAP
contributes to anoikis resistance of circulating human prostate
cancer metastasis precursor cells. Cancer Res. 65:2378–2386. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eto M, Kamiryo Y, Takeuchi A, et al:
Posttransplant administration of cyclophosphamide and donor
lymphocyte infusion induces potent antitumor immunity to solid
tumor. Clin Cancer Res. 14:2833–2840. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Frisch SM and Screaton RA: Anoikis
mechanisms. Curr Opin Cell Biol. 13:555–562. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Banks P, Barker MD and Burton DR:
Recruitment of actin to the cytoskeletons of human monocyte-like
cells activated by complement fragment C5a. Is protein kinase C
involved? Biochem J. 252:765–769. 1988.PubMed/NCBI
|
|
16
|
Monk PN and Banks P: Evidence for the
involvement of multiple signalling pathways in C5a-induced actin
polymerization and nucleation in human monocyte-like cells. J Mol
Endocrinol. 6:241–247. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li K, Fazekasova H, Wang N, et al:
Functional modulation of human monocytes derived DCs by
anaphylatoxins C3a and C5a. Immunobiology. 217:65–73. 2012.
View Article : Google Scholar
|
|
18
|
Bosmann M, Patel VR, Russkamp NF, et al:
MyD88-dependent production of IL-17F is modulated by the
anaphylatoxin C5a via the Akt signaling pathway. FASEB J.
25:4222–4232. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Don MJ, Liao JF, Lin LY and Chiou WF:
Cryptotanshinone inhibits chemotactic migration in macrophages
through negative regulation of the PI3K signaling pathway. Br J
Pharmacol. 151:638–646. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mendoza MC, Er EE, Zhang W, et al:
ERK-MAPK drives lamellipodia protrusion by activating the WAVE2
regulatory complex. Mol Cell. 41:661–671. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Posern G, Saffrich R, Ansorge W and Feller
SM: Rapid lamellipodia formation in nerve growth factor-stimulated
PC12 cells is dependent on Rac and PI3K activity. J Cell Physiol.
183:416–424. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Angelotti ML, Ronconi E, Ballerini L, et
al: Characterization of renal progenitors committed toward tubular
lineage and their regenerative potential in renal tubular injury.
Stem Cells. 30:1714–1725. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hall A: Rho GTPases and the actin
cytoskeleton. Science. 279:509–514. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Z, Hannigan M, Mo Z, et al: Directional
sensing requires G beta gamma-mediated PAK1 and PIX alpha-dependent
activation of Cdc42. Cell. 114:215–227. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Campbell L, Nuttall R, Griffiths D and
Gumbleton M: Activated extracellular signal-regulated kinase is an
independent prognostic factor in clinically confined renal cell
carcinoma. Cancer. 115:3457–3467. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Horiguchi A, Oya M, Uchida A, Marumo K and
Murai M: Elevated Akt activation and its impact on
clinicopathological features of renal cell carcinoma. J Urol.
169:710–713. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Figlin RA, Kaufmann I and Brechbiel J:
Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new
strategies for overcoming resistance to VEGFR and mTORC1
inhibitors. Int J Cancer. 133:788–796. 2013. View Article : Google Scholar : PubMed/NCBI
|
